Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of over- And under- treatment with levothyroxine in primary care in Copenhagen, Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

    Research output: Contribution to journalReviewResearchpeer-review

  4. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Research output: Contribution to journalReviewResearchpeer-review

  1. Bilateral oophorectomy and rate of colorectal cancer: A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treatment options for hypercalcemia after cosmetic oil injections: Lessons from human tissue cultures and a pilot intervention study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Endocrine Disrupting Chemicals and Risk of Testicular Cancer: A Systematic Review and Meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Calcium transport in male reproduction is possibly influenced by vitamin D and CaSR

    Research output: Contribution to journalJournal articleResearchpeer-review

  • D B Allen
  • P Backeljauw
  • M Bidlingmaier
  • B M K Biller
  • M Boguszewski
  • P Burman
  • Graham Butler
  • K Chihara
  • J Christiansen
  • S Cianfarani
  • P Clayton
  • D Clemmons
  • P Cohen
  • F Darendeliler
  • C Deal
  • D Dunger
  • E M Erfurth
  • J S Fuqua
  • A Grimberg
  • M Haymond
  • C Higham
  • K Ho
  • A R Hoffman
  • A Hokken-Koelega
  • G Johannsson
  • A Juul
  • J Kopchick
  • P Lee
  • M Pollak
  • S Radovick
  • L Robison
  • R Rosenfeld
  • R J Ross
  • L Savendahl
  • P Saenger
  • H Toft Sorensen
  • K Stochholm
  • C Strasburger
  • A Swerdlow
  • M Thorner
View graph of relations

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Original languageEnglish
JournalEuropean journal of endocrinology / European Federation of Endocrine Societies
Volume174
Issue number2
Pages (from-to)P1-9
ISSN0804-4643
DOIs
Publication statusPublished - Feb 2015

ID: 45922167